ALT Celebrating Ostomy Awareness Month Date: October

ALT October 28 from 7-8 pm ET Free CME/CE at our Live ECHO® Series Treating Diabetes Beyond A1C: Closing the Gap in Cardio-Kidney Protection Explore risk assessment and individualized treatment strategies for patients with diabetes and CKD. Discuss your de-identified actual cases with our team of experts!  Register Now  This activity has been approved for AMA PRA Category 1 CreditTM This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

ALT ACOG Clinical Practice Guideline ​ - Mental health conditions should be treated during pregnancy and postpartum​ - It is not recommended to discontinue effective psychiatric medication solely because of pregnancy ​ - Shared decision making​ should be emphasized - Treatment decisions must weigh:​ - Risks of untreated illness​ - Medication risks​ - Patient values and preferences​ Perinatal mental health should be managed similarly to other perinatal chronic medical conditions.

ALT ACOG Treatment Recommendations BOX ONE: Mild Symptoms - Psychotherapy (CBT or IPT) BOX TWO: Moderate Depression - Psychotherapy Antidepressant therapy for persistent symptoms BOX THREE: Moderate to Severe Depression - Psychotherapy Combination therapy with psychotherapy BOX FOUR: Severe or Refractory Illness - Psychiatric specialty care Consideration of newer pharmacologic options BOTTOM TEXT: Goal: Symptom remission and functional recovery

ALT Pharmacologic Treatment (ACOG Guidance) LEFT BOX: First-Line Medications - Sertraline - Escitalopram - Fluoxetine RIGHT ARROW RIGHT BOX: Breastfeeding? - Sertraline preferred BOTTOM TEXT: Clinical emphasis: - Continue medications that previously stabilized the patient - Avoid switching medications unnecessarily - Use the lowest effective dose, but avoid undertreatment

ALT Translating Evidence Into ​Obstetric Practice​ Best practices for pharmacologic management include:​ - Treat perinatal depression actively​ - SSRIs remain first-line pharmacotherapy​ - Long-term evidence suggests that use does not harm child development​ Consider emerging therapy:​ - Neuroactive steroids provide rapid symptom relief​ - May fill gap for severe PPD

ALT The Future Potential of Factor XI/Xia Inhibitors to Address Stroke Risk in AF Geoffrey Barnes, MD, MSc  Associate Professor of Internal Medicine Associate Vice Chair, Department of Internal Medicine University of Michigan Medical School Ann Arbor, MI

ALT National Healthcare Quality Week October 18-24

ALT Complimentary CME Series From Screening to Support: Advancing Postpartum Depression Care Advance your approach to identifying postpartum depression, initiating treatment, and improving access to mental health resources through collaborative care.

ALT Celebrating National Health Education Week October 19-24

ALT Essential Tremor: Diagnosing, Managing, and Knowing When to Refer Nandan Lad, MD, PhD Neurosurgeon, Spine Surgeon Duke Health

ALT Complimentary CME The Role of Nerve Transfer Surgery in Severe Cubital Tunnel and High Ulnar Nerve Injuries How can nerve transfer surgery improve patient recovery? Severe cubital tunnel syndrome can cause lasting functional loss, and traditional treatments may be insufficient in advanced cases.

ALT Which factor has most influenced recent changes in ATTR-CM treatment strategies? A. Increased recognition of therapies that target the underlying disease process B. Greater reliance on conventional heart failure medications for disease modification C. Reduced emphasis on pharmacologic treatment in favor of lifestyle interventions D. A shift toward treating ATTR-CM only after progression to advanced heart failure

ALT Advanced Chronic Kidney Disease: How Do We Prolong Life and Avoid Dialysis? A 52-year-old woman with type 2 diabetes and hypertension has stage 4 CKD (eGFR of 20 mL/min/1.73 m²) with progressive decline despite optimal therapy. She reports mild fatigue; labs show significant proteinuria and anemia.

ALT November 4 from 7-8 pm ET Free CME/CE at our Live ECHO® Series Overlooked and Undertreated: Managing Hypertension and CVD When CKD Is in the Picture Explore strategies for optimizing cardiovascular risk management and integrating care when CKD, hypertension, and CVD intersect. Discuss your de-identified actual cases with our team of experts!  Register Now  This activity has been approved for AMA PRA Category 1 CreditTM This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

ALT A graphic with the hashtag “#RiskTipTuesday” and the title Is Your EHR Strengthening Team Communication?” The subhead line reads: “Stronger systems can help reduce malpractice risk and improve patient outcomes.” Below, medical provider in front of a computer. 

ALT A blue and white design titled, “EHR Best Practices”. Infographic for “Support efficient communication”; “Document calls + nontraditional encounters”; “Provide ongoing training for all users” Med-IQ logo at the bottom. 

ALT Complimentary CME Series Collaborating to Improve Multiple Myeloma Care Access Here Explore practical strategies for integrating BCMA-directed therapies, navigating treatment access barriers, and applying emerging evidence in RRMM.

ALT Complimentary Podcast ACC CardiaCast: Future Directions in ATTR-CM Treatment Explore the latest clinical data on investigational and available therapies for ATTR-CM and their potential implications for clinical practice and future research. Faculty: Kevin Alexander, MD, FACC, FHFSA Assistant Professor of Cardiovascular Medicine Stanford University School of Medicine Sarah Cuddy, MBBCh Assistant Professor of Medicine Harvard Medical School Co-Director, Amyloidosis Program Brigham and Women's Hospital

ALT Applying Early Rhythm Control in AF Care Explore evidence, AAD safety data, and shared decision-making strategies

ALT Would these trial results apply to your patient? A patient with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). presents after progression on standard treatment. The clinician is evaluating newly reported data on an investigational targeted therapy. Which question should be answered FIRST before considering how the findings may influence management? A. Did the trial enroll patients with a treatment history similar to this patient's? B. What was the magnitude of the benefit reported? C. How was the therapy administered? D. What was the median duration of follow-up? Check Your Answer